Assessment of Anti–Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis | Zendy

Christopher J. Pannucci | Zendy; Kory I. Fleming | Zendy; Corinne Bertolaccini | Zendy; Ann Marie Prazak | Zendy; Lyen C. Huang | Zendy; T. Bartley Pickron | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Assessment of Anti–Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis

Author(s) -

Christopher J. Pannucci,

Kory I. Fleming,

Corinne Bertolaccini,

Ann Marie Prazak,

Lyen C. Huang,

T. Bartley Pickron

Publication year - 2019

Publication title -

jama surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.757

H-Index - 176

eISSN - 2168-6262

pISSN - 2168-6254

DOI - 10.1001/jamasurg.2019.1165

Subject(s) - medicine , colorectal surgery , enoxaparin sodium , guideline , randomized controlled trial , surgery , venous thromboembolism , clinical trial , anesthesia , abdominal surgery , low molecular weight heparin , heparin , thrombosis , pathology

Between 4% and 12% of patients undergoing colorectal surgery and receiving enoxaparin, 40 mg per day, have a postoperative venous thromboembolism (VTE) event. An improved understanding of why "breakthrough" VTE events occur despite guideline-compliant prophylaxis is an important patient safety question.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research